The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Chemotherapy Induced Peripheral Neuropathy Treatment-Global Market Insights and Sales Trends 2025
Synopsis
CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.
The global Chemotherapy Induced Peripheral Neuropathy Treatment market size is expected to reach US$ 2599.2 million by 2029, growing at a CAGR of 6.4% from 2023 to 2029. The market is mainly driven by the significant applications of Chemotherapy Induced Peripheral Neuropathy Treatment in various end use industries. The expanding demands from the Platinum Agents, Taxanes, Vinca Alkaloids and Others, are propelling Chemotherapy Induced Peripheral Neuropathy Treatment market. Calcium Channel α2-delta Ligands, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Antidepressants segment is estimated at % CAGR for the next seven-year period.
Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.
The key players are Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor etc.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Chemotherapy Induced Peripheral Neuropathy Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Chemotherapy Induced Peripheral Neuropathy Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Chemotherapy Induced Peripheral Neuropathy Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Chemotherapy Induced Peripheral Neuropathy Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Chemotherapy Induced Peripheral Neuropathy Treatment covered in this report include Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc and DermaXon LLC, etc.
The global Chemotherapy Induced Peripheral Neuropathy Treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
PeriphaGen
Apexian Pharma
WinSanTor
Global Chemotherapy Induced Peripheral Neuropathy Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Chemotherapy Induced Peripheral Neuropathy Treatment market, Segment by Type:
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others
Global Chemotherapy Induced Peripheral Neuropathy Treatment market, by Application
Platinum Agents
Taxanes
Vinca Alkaloids
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Chemotherapy Induced Peripheral Neuropathy Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.
The global Chemotherapy Induced Peripheral Neuropathy Treatment market size is expected to reach US$ 2599.2 million by 2029, growing at a CAGR of 6.4% from 2023 to 2029. The market is mainly driven by the significant applications of Chemotherapy Induced Peripheral Neuropathy Treatment in various end use industries. The expanding demands from the Platinum Agents, Taxanes, Vinca Alkaloids and Others, are propelling Chemotherapy Induced Peripheral Neuropathy Treatment market. Calcium Channel α2-delta Ligands, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Antidepressants segment is estimated at % CAGR for the next seven-year period.
Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.
The key players are Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor etc.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Chemotherapy Induced Peripheral Neuropathy Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Chemotherapy Induced Peripheral Neuropathy Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Chemotherapy Induced Peripheral Neuropathy Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Chemotherapy Induced Peripheral Neuropathy Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Chemotherapy Induced Peripheral Neuropathy Treatment covered in this report include Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc and DermaXon LLC, etc.
The global Chemotherapy Induced Peripheral Neuropathy Treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
PeriphaGen
Apexian Pharma
WinSanTor
Global Chemotherapy Induced Peripheral Neuropathy Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Chemotherapy Induced Peripheral Neuropathy Treatment market, Segment by Type:
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others
Global Chemotherapy Induced Peripheral Neuropathy Treatment market, by Application
Platinum Agents
Taxanes
Vinca Alkaloids
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Chemotherapy Induced Peripheral Neuropathy Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment by Type
1.2.1 Calcium Channel α2-delta Ligands
1.2.2 Antidepressants
1.2.3 Opioids
1.2.4 Others
1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type
1.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Overview by Type (2018-2029)
1.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size Review by Type (2018-2023)
1.3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2018-2023)
1.4.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2018-2023)
2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Competition by Company
2.1 Global Top Players by Chemotherapy Induced Peripheral Neuropathy Treatment Sales (2018-2023)
2.2 Global Top Players by Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2018-2023)
2.3 Global Top Players by Chemotherapy Induced Peripheral Neuropathy Treatment Price (2018-2023)
2.4 Global Top Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base Distribution, Sales Area, Product Type
2.5 Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Situation and Trends
2.5.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2022)
2.7 Date of Key Manufacturers Enter into Chemotherapy Induced Peripheral Neuropathy Treatment Market
2.8 Key Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Chemotherapy Induced Peripheral Neuropathy Treatment Status and Outlook by Region
3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size by Region
3.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Region (2018-2023)
3.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Value by Region (2018-2023)
3.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Region
3.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Region (2024-2029)
3.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Value by Region (2024-2029)
3.3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Chemotherapy Induced Peripheral Neuropathy Treatment by Application
4.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment by Application
4.1.1 Platinum Agents
4.1.2 Taxanes
4.1.3 Vinca Alkaloids
4.1.4 Others
4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application
4.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Overview by Application (2018-2029)
4.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size Review by Application (2018-2023)
4.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2018-2023)
4.3.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2018-2023)
5 North America Chemotherapy Induced Peripheral Neuropathy Treatment by Country
5.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size by Country
5.1.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Country (2018-2023)
5.1.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Value by Country (2018-2023)
5.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Country
5.2.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Country (2024-2029)
5.2.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Value by Country (2024-2029)
6 Europe Chemotherapy Induced Peripheral Neuropathy Treatment by Country
6.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size by Country
6.1.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Country (2018-2023)
6.1.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Value by Country (2018-2023)
6.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Country
6.2.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Country (2024-2029)
6.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Value by Country (2024-2029)
7 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment by Region
7.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size by Region
7.1.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Region
7.2.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Value by Region (2024-2029)
8 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment by Country
8.1 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size by Country
8.1.1 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Country (2018-2023)
8.1.3 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Value by Country (2018-2023)
8.2 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Country
8.2.1 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Country (2024-2029)
8.2.2 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Value by Country (2024-2029)
9 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment by Country
9.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size by Country
9.1.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Country
9.2.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Aptinyx Inc
10.1.1 Aptinyx Inc Company Information
10.1.2 Aptinyx Inc Introduction and Business Overview
10.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
10.1.5 Aptinyx Inc Recent Development
10.2 Asahi Kasei Pharma Corp
10.2.1 Asahi Kasei Pharma Corp Company Information
10.2.2 Asahi Kasei Pharma Corp Introduction and Business Overview
10.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
10.2.5 Asahi Kasei Pharma Corp Recent Development
10.3 Regenacy Pharmaceuticals
10.3.1 Regenacy Pharmaceuticals Company Information
10.3.2 Regenacy Pharmaceuticals Introduction and Business Overview
10.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
10.3.5 Regenacy Pharmaceuticals Recent Development
10.4 MAKScientific LLC
10.4.1 MAKScientific LLC Company Information
10.4.2 MAKScientific LLC Introduction and Business Overview
10.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
10.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
10.4.5 MAKScientific LLC Recent Development
10.5 Metys Pharmaceuticals AG
10.5.1 Metys Pharmaceuticals AG Company Information
10.5.2 Metys Pharmaceuticals AG Introduction and Business Overview
10.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
10.5.5 Metys Pharmaceuticals AG Recent Development
10.6 Nemus Bioscience Inc
10.6.1 Nemus Bioscience Inc Company Information
10.6.2 Nemus Bioscience Inc Introduction and Business Overview
10.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
10.6.5 Nemus Bioscience Inc Recent Development
10.7 PledPharma
10.7.1 PledPharma Company Information
10.7.2 PledPharma Introduction and Business Overview
10.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
10.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
10.7.5 PledPharma Recent Development
10.8 Sova Pharmaceuticals Inc
10.8.1 Sova Pharmaceuticals Inc Company Information
10.8.2 Sova Pharmaceuticals Inc Introduction and Business Overview
10.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
10.8.5 Sova Pharmaceuticals Inc Recent Development
10.9 DermaXon LLC
10.9.1 DermaXon LLC Company Information
10.9.2 DermaXon LLC Introduction and Business Overview
10.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
10.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
10.9.5 DermaXon LLC Recent Development
10.10 Kineta Inc
10.10.1 Kineta Inc Company Information
10.10.2 Kineta Inc Introduction and Business Overview
10.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
10.10.5 Kineta Inc Recent Development
10.11 Krenitsky Pharmaceuticals Inc
10.11.1 Krenitsky Pharmaceuticals Inc Company Information
10.11.2 Krenitsky Pharmaceuticals Inc Introduction and Business Overview
10.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
10.11.5 Krenitsky Pharmaceuticals Inc Recent Development
10.12 PeriphaGen
10.12.1 PeriphaGen Company Information
10.12.2 PeriphaGen Introduction and Business Overview
10.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
10.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
10.12.5 PeriphaGen Recent Development
10.13 Apexian Pharma
10.13.1 Apexian Pharma Company Information
10.13.2 Apexian Pharma Introduction and Business Overview
10.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
10.13.5 Apexian Pharma Recent Development
10.14 WinSanTor
10.14.1 WinSanTor Company Information
10.14.2 WinSanTor Introduction and Business Overview
10.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
10.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
10.14.5 WinSanTor Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis
11.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Dynamics
11.4.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Trends
11.4.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers
11.4.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
11.4.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors
12.3 Chemotherapy Induced Peripheral Neuropathy Treatment Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
